New drug combo aims to extend remission in ovarian cancer

NCT ID NCT07225270

Recruiting now Disease control Sponsor: Genmab Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 4 times

Summary

This Phase 3 trial tests whether adding the experimental drug Rina-S to standard care (bevacizumab or monitoring) can help keep platinum-sensitive ovarian cancer from returning after chemotherapy. About 528 participants will receive either Rina-S alone, Rina-S plus bevacizumab, bevacizumab alone, or monitoring only. The study measures how long the cancer stays under control and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rinatabart sesutecan (Rina-S) and bevacizumab
What this could lead to: If successful, this could offer a new maintenance option to help keep platinum-sensitive ovarian cancer from returning after chemotherapy.
What could go wrong: This is an early-stage Phase 3 trial, so results are not yet proven. Side effects from Rina-S or bevacizumab may occur, and the combination may not improve outcomes over standard care alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer ovarian carcinoma ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma primary peritoneal carcinoma primary sclerosing cholangitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER PLATINUM-SENSITIVE OVARIAN CANCER PSOC

Contacts and locations

Locations

Hyogo Cancer Center
RECRUITING

Akashi, Hyōgo, Japan
Kanagawa Prefectural Cancer Center
RECRUITING

Yokohama, Japan
Kitasato University Hospital
RECRUITING

Sagamihara, Japan
Miami Valley Hospital South
RECRUITING

Centerville, Ohio, 45459, United States
Mie University Graduate School Of Medicine
RECRUITING

Tsu, Mie-ken, Japan
Mt. Sinai Comprehensive Cancer Center
RECRUITING

Miami, Florida, 33140, United States
National Hospital Organization Hokkaido Cancer Center
RECRUITING

Sapporo, Hokkaido, Japan
Niigata University Medical & Dental Hospital
RECRUITING

Niigata, Japan
Okayama University Hospital
RECRUITING

Okayama, Japan
Osaka Medical and Pharmaceutical University Hospital
RECRUITING

Takatsuki, Osaka, Japan
Saitama Medical University International Medical Center
RECRUITING

Hidaka, Saitama, Japan
Sapporo Medical University Hospital
RECRUITING

Sapporo, Hokkaido, Japan
Sarasota Memorial Health Care System
RECRUITING

Sarasota, Florida, 34239, United States
The Cancer Institute Hospital of JFCR
RECRUITING

Tokyo, Japan
The Jikei University Kashiwa Hospital
RECRUITING

Kashiwa, Japan
Zangmeister Cancer Center
RECRUITING

Columbus, Ohio, 43219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.